Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Design Therapeutics Inc (NQ: DSGN )

2.270 -0.030 (-1.30%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 4, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 271,338
Open 2.280
Bid (Size) 2.200 (40)
Ask (Size) 2.310 (50)
Prev. Close 2.300
Today's Range 2.190 - 2.290
52wk Range 1.940 - 17.48
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Over $5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
The Dow Jones closed slightly higher on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in... 
Via Benzinga
Topics Stocks
Exposures US Equities
Market Sentiment Teeters As US Indices, Including S&P 500, Break Key Supports: Next Levels To Watch
All three leading U.S. stock indices — the S&P 500, Nasdaq 100, and Russell 2000 — have simultaneously breached a crucial technical support level this week. 
Via Benzinga
Topics Stocks
Exposures US Equities

Performance

YTD
-76.77%
-76.77%
1 Month
-11.33%
-11.33%
3 Month
-65.34%
-65.34%
6 Month
-59.25%
-59.25%
1 Year
-86.12%
-86.12%

More News

Read More
Design Therapeutics' Modified DT-216 May Have Potential, But Analyst Awaits Further Developments
Via Benzinga
Nasdaq Falls 100 Points; Siyata Mobile Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures US Equities
Why Shares of Design Therapeutics Are Plummeting on Tuesday
Via The Motley Fool
Why PhenomeX Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Crude Oil Down 2%; Home Depot Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Benzinga's Top Ratings Upgrades, Downgrades For August 15, 2023
Via Benzinga
Dow Falls Over 200 Points; US Retail Sales Top Expectations
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Is Design Therapeutics Stock Moving Lower Today?
Via Benzinga
Why Delcath Systems Shares Are Trading Higher By Around 58%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Exposures Product Safety
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Design Therapeutics, Getty Images, Sea Limited And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Design Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial Results
From Design Therapeutics, Inc.
Via GlobeNewswire
Design Therapeutics Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich Ataxia
From Design Therapeutics, Inc.
Via GlobeNewswire
Reata's Acquisition Fits Biogen's Strategy Despite High Cost: Analyst Says High Level Regulatory Scrutiny Not Anticipated
Via Benzinga
Why American Equity Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Design Therapeutics to Present at the 2023 Jefferies Healthcare Conference
From Design Therapeutics, Inc.
Via GlobeNewswire
Design Therapeutics Provides Pipeline Updates and Reports First Quarter 2023 Financial Results
From Design Therapeutics, Inc.
Via GlobeNewswire
Why Hibbett Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2023
Via Benzinga
Design Therapeutics to Present Preclinical Data on its GeneTAC™ Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023
From Design Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.